Market Overview
The sleep disorders market is projected to grow from USD 25.03 billion in 2024 to USD 66.55 billion by 2034 at a CAGR of 10.3%. Sleep disorders affect the quality, timing, and duration of sleep, leading to daytime fatigue and other health problems. Common conditions include insomnia, sleep apnea, narcolepsy, which involves excessive daytime sleepiness, and restless legs syndrome, an uncontrollable urge to move the legs while resting. Their market share and growth rates are comparatively lower because of less widespread awareness and the more complex nature of diagnosis and treatment. Sleep disorders can result from stress, medical conditions, lifestyle habits, or genetics, so proper diagnosis and treatment are essential. By product, diagnostics held the larger share in 2024, and high treatment costs are identified as a restraint.
Remote Care Expands Access to Sleep Specialists
Telemedicine has become a significant trend, driven by the need for remote healthcare solutions and accessible treatment options. The COVID-19 pandemic accelerated adoption, and the American Academy of Sleep Medicine reported that telemedicine consultations for sleep-related issues grew by over 50% during the pandemic. Providers use virtual platforms for consultations, remote patient monitoring, and follow-up care for conditions such as insomnia and sleep apnea, which reduces barriers to care and allows greater access to specialized sleep experts.
Growing Preference for Non-Drug Therapy
There is a growing shift toward non-pharmacological treatments, particularly cognitive behavioral therapy for insomnia (CBT-I), which focuses on changing behaviors and thought patterns that contribute to insomnia. The American College of Physicians recommends it as the first-line treatment for chronic insomnia, and a 2020 JAMA Internal Medicine study found it significantly improved sleep outcomes in over 70% of individuals with chronic insomnia. Mindfulness practices, relaxation techniques, and biofeedback are also gaining traction for their minimal side effects.
This shift supports the therapeutics segment, which is expected to register a higher growth rate during the forecast period. Europe also reflects the trend through a rising preference for non-pharmacological treatments such as cognitive behavioral therapy for insomnia.
Regional and Competitive Insights
North America holds the largest market share, driven by high prevalence and strong healthcare infrastructure. Europe is a significant market, with Germany, the UK, and France leading, supported by high healthcare standards, government initiatives, an aging population, and rising rates of conditions such as obesity that contribute to sleep disorders, while Asia Pacific is experiencing rapid growth in China, Japan, and India due to lifestyle changes, urbanization, and an aging population.
Browse In-depth Market Research Report:
https://www.polarismarketresearch.com/industry-analysis/sleep-disorder-market
Companies are increasingly collaborating with healthcare institutions and investing in telemedicine services for remote monitoring and treatment. In August 2025, digital sleep clinic Dreem Health partnered with Moona Health, DrLullaby, and Daybreak to expand integrated sleep care solutions. In July 2025, the National Sleep Foundation announced a family-focused sleep health initiative aimed at improving sleep outcomes across diverse populations.
For new entrants, the report points to expanding into telemedicine for remote consultations, integrating telehealth platforms for continuous patient monitoring, and offering cognitive behavioral therapy for insomnia for a competitive edge, alongside a focus on emerging markets where healthcare access and awareness are improving.
Key Players in the Sleep Disorders Market
- ResMed
- Philips Healthcare
- Medtronic
- Fisher & Paykel Healthcare
- Somnomed
- Sleep Number Corporation
- Invacare Corporation
- Nihon Kohden Corporation
- CareFusion
- Becton Dickinson
- Circadia
- Inogen
- Itamar Medical
- ProTech Sleep Solutions
Conclusion
The sleep disorders market, projected at USD 66.55 billion by 2034, is being shaped by remote care and behavioral approaches. Telemedicine, non-pharmacological treatments, and cognitive behavioral therapy for insomnia are widening access, while awareness gaps around narcolepsy and restless legs syndrome point to areas where diagnosis and education still matter for suppliers and providers.
More Trending Latest Reports By Polaris Market Research:
Online Trading Platform Market
English
French
Spanish
Deutsch
Turkish
Italiano